^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Thyroid Gland Anaplastic Carcinoma |
| Drug: | AIC100 (ICAM-1-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
AffyImmune Therapeutics' AIC100 Granted Fast Track Designation for Treating Thyroid Cancer
Published date:
05/17/2021
Excerpt:
AffyImmune Therapeutics...announced today that the US Food and Drug Administration (FDA) granted Fast Track designation to its lead compound, AIC100, for the treatment of anaplastic thyroid cancer and refractory poorly differentiated thyroid cancer.
